# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN-TD
- Date: 1980-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rena Hawkfeather-Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She wants to know why her eyelids droop and her arms give out, after a year of hard recovery **S**
- She wants to keep working for her community **S**
- She wants care that respects her as a Cherokee woman, close to home where possible, with her own medicine respected **S**

## Your goals

- A confirmed diagnosis and treatment plan within three weeks. Target: 1980-03-23. Recorded outcome: AChR antibodies, nerve stimulation, chest CT and kidney ultrasound done; generalized MG diagnosed and treatment begun at two weeks. **S**
- Minimal manifestation status (MG-ADL 0 to 1) within a year, with prednisone at 7.5 mg or less. Target: 1980-10-12. Recorded outcome: MG-ADL 7 at diagnosis, 1 at seven months; prednisone 15 mg and still tapering. **S**
- No myasthenic crisis, and she knows the warning signs and the medicines to avoid. Target: 1980-10-12. Recorded outcome: No crisis; FVC 3.25 to 3.62 L; she carries a wallet card and the list of medicines to avoid. **S**
- Kidney health: eGFR and urine albumin yearly, home blood pressure 110/75 mm Hg or lower if it rises above 130/85, 2 to 3 liters of water a day, and no NSAIDs. Target: 1980-10-12. Recorded outcome: eGFR normal; urine albumin normal; home blood pressure about 116/74 without medicine. **S**
- Return to full-time work for the Cherokee Nation. Target: 1980-10-12. Recorded outcome: Back at work full time from the seventh month. **S**

## What we agreed to do

- Neuromuscular neurology consultation within two weeks for suspected generalized myasthenia gravis: diagnosis, immunotherapy, thymectomy and safety. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory force. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycin. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026) **S**
- Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDs. Guideline: KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025) **S**
- Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further asked. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cherokee Nation Health Services (2026) **S**
- Immunotherapy: pyridostigmine 60 mg four times daily; prednisone 10 mg each morning rising by 10 mg a week to 40 mg; azathioprine after TPMT activity and hepatitis B and tuberculosis screening, from 50 mg to 150 mg daily; pneumococcal and recombinant zoster vaccines before immunosuppression; no live vaccines. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Thymectomy: thoracic surgery assessment for robotic extended thymectomy once she is stable, for AChR antibody-positive generalized MG at 34. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Wolfe GI, et al. Randomized Trial of Thymectomy in Myasthenia Gravis (MGTX). N Engl J Med 2016;375(6):511-522 (2016) **S**
- Glucocorticoid safety: calcium and vitamin D, DXA within the first months, glucose and hemoglobin A1c, blood pressure and weight at each visit, sleep and mood, eye examination yearly, and Pneumocystis prophylaxis while prednisone is 20 mg or more with azathioprine. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022) **S**
- Azathioprine monitoring: blood count and liver tests every one to two weeks for the first two months, then every three months. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Newer targeted therapies (efgartigimod, eculizumab or ravulizumab) kept in reserve for refractory disease or intolerance of standard immunotherapy; complement inhibitors would need meningococcal vaccination first. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT). Lancet Neurol 2021;20(7):526-536 (2021) **S**
- Standing laboratory orders at the Cherokee Nation Health Services clinic near her home for every azathioprine blood test, with results sent to this clinic and a nurse call for each result. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cherokee Nation Health Services (2026) **S**

## Follow-up

- 1980-03-09: New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral **S**
- 1980-03-23: Two-week review with the neuromuscular neurology consultation the same day: antibody, nerve stimulation, chest CT and kidney ultrasound results, the diagnosis, and the treatment plan **S**
- 1980-05-04: Six-week review on pyridostigmine and prednisone: strength, breathing, glucose and blood pressure, bone density, start of azathioprine, and the thymectomy plan **S**
- 1980-07-13: Review five weeks after thymectomy: recovery, pathology, azathioprine monitoring, the prednisone taper, and kidney care **S**
- 1980-08-24: Periodic adult preventive visit **S**
- 1980-10-12: Seven-month review: minimal manifestation status, prednisone and pyridostigmine reduction, azathioprine safety, kidney screening, and plans for the year **S**

This teaching document does not replace care from a qualified clinician.
